Rosenpark Research GmbH

Darmstadt, Hesse 64283

1 studies enrolling now · 5 studies all time

What they study most

Active Nonsegmental Vitiligo, Atopic Dermatitis, Chronic Spontaneous Urticaria, Eczema, Psoriasis, Stable Nonsegmental Vitiligo

Studies at this site

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Running, not enrolling
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early